We are live on ! Find out more
FCMI

Foresite Capital Management IV Portfolio holdings

AUM $237M
1-Year Est. Return 107.53%
This Fund
S&P 500
This Quarter Est. Return
+42.75%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$198M
AUM Growth
+$17.8M
Cap. Flow
-$40.7M
Cap. Flow %
-20.58%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
1
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
PHVS icon
Pharvaris
PHVS
+$5.98M

Top Sells

Rank Stock Value
1
CBAY
Cymabay Therapeutics
CBAY
+$26.6M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$19.2M
3
LYEL icon
Lyell Immunopharma
LYEL
+$828K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
1
Pharvaris
PHVS
$2.28B
$113M 57.25%
4,038,842
+295,392
+8% +$5.98M
KURA icon
2
Kura Oncology
KURA
$800M
$26.6M 13.44%
1,849,947
– –
KNTE
3
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$22.9M 11.58%
9,671,643
– –
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$1.69B
$18.9M 9.56%
875,000
– –
LYEL icon
5
Lyell Immunopharma
LYEL
$317M
$16.2M 8.16%
416,250
-22,991
-5% -$828K
ACRS icon
6
Aclaris Therapeutics
ACRS
$726M
– –
-2,808,034
Closed -$19.2M
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
– –
-1,787,094
Closed -$26.6M

Similar funds

BCM
Birmingham Capital Management Birmingham, Alabama $237M AUM 32.7% 1-Year Est. Return
AG
ASO Group Road Town $237M AUM
FL
FreeGulliver LLC New Orleans, Louisiana $237M AUM 21.92% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
MFA
Millington Financial Advisors Naperville, Illinois $237M AUM 22.22% 1-Year Est. Return
TCM
Tekne Capital Management New York $237M AUM 62.98% 1-Year Est. Return
WW
Windle Wealth Oklahoma City, Oklahoma $237M AUM 22.79% 1-Year Est. Return
CB
CNB Bank Clearfield, Pennsylvania $238M AUM 26.55% 1-Year Est. Return

Foresite Capital Management IV's Q4 2023 Portfolio in Review

As of Q4 2023, Foresite Capital Management IV held 7 positions worth $198M, up 9.9% from $180M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management IV withdrew a net $40.7M in Q4 2023, closing 2 positions and reducing 1 holding. Its most notable exit was Cymabay Therapeutics, an estimated $26.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Foresite Capital Management IV added an estimated $5.98M to Pharvaris.

  • Foresite Capital Management IV added most to Pharvaris in Q4 2023, an estimated $5.98M increase.
  • Foresite Capital Management IV's biggest Q4 2023 reduction was Lyell Immunopharma, cutting an estimated $828K.
  • Foresite Capital Management IV fully exited Cymabay Therapeutics in Q4 2023, selling an estimated $26.6M.
  • Foresite Capital Management IV's ten largest holdings make up 100% of its $198M portfolio in Q4 2023.
  • Foresite Capital Management IV opened 0 new positions and closed 2 in Q4 2023.
  • Foresite Capital Management IV's portfolio value rose 9.9% quarter-over-quarter to $198M.

Based on Foresite Capital Management IV's 13F filing for Q4 2023, filed 13 Feb 2024.